{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"274"},{"groupId":"OG004","value":"94"}]}],"title":"At least one treatment-emergent adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"157"},{"groupId":"OG004","value":"45"}]}],"title":"Serious adverse events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"278"},{"groupId":"OG004","value":"95"}],"units":"Participants"}],"description":"Number of participants with adverse events and serious adverse events, including clinically relevant physical examinations and laboratory measurements","groups":[{"description":"Participants received 40 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG000","title":"Part 1: 40 mg QD"},{"description":"Participants received 80 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG001","title":"Part 1: 80 mg QD"},{"description":"Participants received 160 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG002","title":"Part 1: 160 mg QD"},{"description":"Part 1: Participants received 160 mg of zanubrutinib twice daily (BID) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up. Part 2: This dose regimen was selected for further evaluation in various expansion cohorts that span multiple disease types.","id":"OG003","title":"Parts 1 and 2: 160 mg BID"},{"description":"Part 1: Participants received 320 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up. Part 2: This dose regimen was selected for further evaluation in various expansion cohorts that span multiple disease types.","id":"OG004","title":"Parts 1 and 2: 320 mg QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Analysis Set included all participants who received ≥ 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to approximately 6 years and 7 months","title":"Part 1 and Part 2: Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}